Episode 128: Debate of the Decade: RCTs in the Era of Precision Oncology
Healthcare Unfiltered
00:00
The Importance of Comparative Data
Vivek: We need to use the tools we've been given by nature, which is randomization and use it in a more intelligent fashion. I would probably definitely, if the insurance is able to approve, start them on an intrac inhibitor or a retinubiter. Chris: There will be a handful of circumstances every few years where the drugs are just so promising.
Play episode from 40:52
Transcript
